Shots:

• The US FDA has granted BTD for apabetalone in combination with SOC including high-intensity statins- for the secondary prevention of MACE in patients with T2D Mellitus and recent acute coronary syndrome
• In 2019- Resverlogix reported results of P-III BETonMACE that showed a reduction in hospitalizations due to CHF as well as improving CV outcomes in two pre-specified subpopulations including those with CKD
• Apabetalone is a first-in-class- BET inhibitor selective for the second bromodomain (BD2) within the BET proteins

 ­ Ref: GLOBE NEWSWIRE | Image: Resverlogix